Novel agents, such as BTK inhibitors, BCL2 inhibitors, PD-1 monoclonal antibodies, and epigenetic agents, such as Decitabine, Azacitidine, and Cidabenamide, have demonstrated promising efficacy and a manageable safety profile in patients with primary or relapsed refractory lymphoma, either alone or in combination with CHOP or R-CHOP regimens (10–15). The gene discussed is BCL2; the disease is lymphoma.